StockNews.AI
MLYS
StockNews.AI
147 days

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

1. Mineralys will host a webinar on clinical trial results. 2. Dr. Luke Laffin will discuss lorundrostat and hypertension. 3. The focus is on unmet needs in hypertension treatments. 4. Lorundrostat targets diseases driven by dysregulated aldosterone.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial outcomes can enhance investor confidence, similar to prior biotech successes.

How important is it?

The discussion of clinical trials is significant for MLYS’s stock given its pipeline's potential.

Why Short Term?

The upcoming webinar may trigger immediate investor interest and short-term stock movement.

Related Companies

AMGNGILDJNJ
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension March 25, 2025 08:00 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar featuring Dr. Luke Laffin of the Cleveland Clinic, who will discuss the latest results from the pivotal Advance-HTN and Launch-HTN clinical trials, and offer his perspective on the unmet medical need in uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), and the potential of lorundsrostat to change the current treatment paradigm. Tuesday, April 1st @ 8:00 a.m. ETDomestic:  1-877-704-4453 International:   1-201-389-0920Webcast:  Link A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website. About Mineralys TherapeuticsMineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter. Contact:Investor Relationsinvestorrelations@mineralystx.com Media RelationsTom WeibleElixir Health Public RelationsPhone: (1) 515-707-9678Email: tweible@elixirhealthpr.com

Related News